Skip to main content

Day: August 3, 2021

Eezy Plc: Invitation to briefing on the Q2/2021 interim report

EEZY PLC —   INVESTOR NEWS — 3 AUGUST 2021 AT 10:45 Eezy Plc: Invitation to briefing on the Q2/2021 interim report Eezy Plc will publish the Interim report for 1-6/2021 on Tuesday 10 August 2021 approx. at 8.00. A Finnish-language briefing for investors, analysts and media will be held on 10 August 2021 at 13.00 Finnish time as webcast athttps://eezy.videosync.fi/2021-q2-tulos    The webcast will be hosted by CEO Sami Asikainen and CFO Hannu Nyman. During the presentation, there will be an opportunity to ask questions. A recording of the webcast will be later available at the company’s website.Further information: Hannu NymanCFOEezy Plchannu.nyman@eezy.fitel. +358 (0)50 306 9913

Continue reading

Publication of eQ Plc’s 2021 half year financial report and invitation to result presentation

eQ Plc Investor news3 August 2021, at 10:45 a.m. eQ Plc will publish its January-June 2021 half year financial report on Tuesday 10 August 2021 at around 8:00 a.m. eQ will present the result to press, investors and analysts in a press conference to be held on 10 August 2021 at 11:00 a.m. The press conference will held via webcast. The webcast participation requires a registration. The press conference will be held in Finnish. The presentation material can be viewed at eQ’s website after the press conference has begun. To join the press conference, please register with iida.tuunainen@eq.fi. eQ Plc Additional information: Antti Lyytikäinen, CFO, tel. +358 9 6817 8741 Distribution: Nasdaq Helsinki, www.eQ.fi, media eQ Group is a Finnish group of companies specialising in asset management and corporate finance business. eQ Asset Management...

Continue reading

Within Weeks of Launching in Georgia, TAAT™ is Now Sold in More Than 70 Stores Statewide

Picture 1The Company’s initial shipment of TAAT™ arrived in Georgia in late June 2021 and was completely pre-sold upon arrival. As of this writing, TAAT™ is carried in more than 70 stores across the state of Georgia.LAS VEGAS and VANCOUVER, British Columbia, Aug. 03, 2021 (GLOBE NEWSWIRE) — TAAT™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT™”) is pleased to announce that its flagship product TAAT™ has recently been placed in 71 new retail points of sale throughout the state of Georgia, bringing its total store count in the United States to more than 400 as of the beginning of this month. In a press release dated June 25, 2021, the Company stated it had pre-sold its entire initial shipment of 15 master cases of TAAT™ to a distributor based in Alpharetta, Georgia with...

Continue reading

Advantest’s Virtual VOICE 2021 Developer Conference Achieves Record-High Attendance

The First-Ever Virtual VOICE Reached Over 300 International Attendees TOKYO, Aug. 03, 2021 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation’s (TSE: 6857) Virtual VOICE 2021 Developer Conference attracted record attendance from the international test community when it convened on June 21-23. Altogether, 320 people attended the 3-day event, 54 percent of whom represented Advantest customers and partners. Ninety-seven percent of the attendees who responded to a post-event survey gave the conference a “recommend” rating. “The success of the first Virtual VOICE Developer Conference is a testament to the dedication and hard work of the customers and Advantest staff that comprise the VOICE 2021 Steering Committee,” said Doug Lefever, president and CEO of Advantest America. “When the decision...

Continue reading

Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development

GUANGZHOU, China, Aug. 03, 2021 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of synthetic lethality. The two companies will jointly develop CDx for a targeted oncology drug, Senaparib (IMP4297), a PARP inhibitor, for the treatment of prostate cancer globally, including CDx submissions to both the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration of China (NMPA). The global program will be supported by Burning Rock’s Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs in Guangzhou, China and California, U.S. Furthermore, the two...

Continue reading

Ovation Fertility Washington DC Announced as Ovation’s Newest Lab Location

Ovation Fertility Washington DC joins a growing list of state-of-the-art IVF laboratories to partner with Ovation Fertility and join the next generation of fertility care providers.Conor Beardsley, President, Ovation FertilityLos Angeles, Aug. 03, 2021 (GLOBE NEWSWIRE) — Ovation® Fertility proudly announces the addition of its newest laboratory, in Washington DC, bringing the IVF services company’s total number of nationwide IVF labs to 11. With Ovation’s acquisition of its IVF lab, Columbia Fertility Associates joins a growing list of renowned physician practices choosing to partner with Ovation to help patients become parents. The addition of Ovation Fertility Washington DC adds another major city market to the national company’s existing group of IVF and andrology labs across the United States, and expands...

Continue reading

Ovation Fertility Washington DC Announced as Ovation’s Newest Lab Location

Ovation Fertility Washington DC joins a growing list of state-of-the-art IVF laboratories to partner with Ovation Fertility and join the next generation of fertility care providers.Conor Beardsley, President, Ovation FertilityLos Angeles, Aug. 03, 2021 (GLOBE NEWSWIRE) — Ovation® Fertility proudly announces the addition of its newest laboratory, in Washington DC, bringing the IVF services company’s total number of nationwide IVF labs to 11. With Ovation’s acquisition of its IVF lab, Columbia Fertility Associates joins a growing list of renowned physician practices choosing to partner with Ovation to help patients become parents. The addition of Ovation Fertility Washington DC adds another major city market to the national company’s existing group of IVF and andrology labs across the United States, and expands...

Continue reading

Stellantis N.V. H1 2021 RESULTS

Following is a summary of the “Stellantis N.V. H1 2021 RESULTS” press release. A PDF of the complete press release is attached to this email. The document is also available in the media section of the Stellantis corporate website: https://www.stellantis.com  Stellantis Reports Record H1 Pro Forma Results with 11.4% Margin, All Segments Profitable. Full-Year Guidance Raised to ~10% Adjusted Operating Income Margin  AttachmentStellantis NV H1 2021 Earnings Release_Final

Continue reading

Societe Generale: Second quarter and half-year 2021 results

RESULTS AT JUNE 30TH 2021    Press releaseParis, August 3rd 2021 EXCELLENT PERFORMANCE IN ALL THE BUSINESSES IN Q2 21 AND H1 21 In Q2 21, revenues up +18.2% vs. Q2 20 (+20.5%*), with a strong quarter in Global Banking & Investor Solutions, substantial growth in Financial Services and a rebound in Retail Banking Strong positive jaws effect in all the businesses Underlying gross operating income of EUR 2 billion(1), up 55%(1) vs. Q2 20 Low cost of risk at 11 basis points in Q2 21; continued prudent approach in terms of provisioning Underlying Group net income of EUR 1.35 billion(1), reported Group net income (including IFRIC 21 charges and exceptional items) of EUR 1.44 billion in Q2 21 Profitability (ROTE) at 10.4%(1) and 11.2% in Q2 21 In H1 21, underlying gross operating income of EUR 4.2 billion(1), up +83.4%(1) vs....

Continue reading

ECMOHO Limited Announces Pricing of US$9 Million Underwritten Public Offering of American Depositary Shares

SHANGHAI, China, Aug. 03, 2021 (GLOBE NEWSWIRE) — ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), an integrated solutions provider in the health and wellness market in China, today announced the pricing of an underwritten public offering of 10 million American Depositary Shares (“ADSs”) at an offering price of US$0.90 per ADS for gross proceeds to the Company of US$9 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, and assuming the underwriter does not exercise the option to purchase additional ADSs. Each ADS represents four Class A ordinary shares of the Company. The Company intends to use the net proceeds from this offering for investment in its SaaS platform, working capital and general corporate purposes. The closing of the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.